Posted by Michael Wonder on 28 Jul 2021
Apic Bio receives FDA fast track designation for APB-102 for the treatment of patients with SOD1 ALS
28 July 2021 - Apic Bio today announced that the U.S. FDA has granted fast track designation to APB-102, the Company’s lead gene therapy candidate designed to treat SOD1 amyotrophic lateral sclerosis.
APB-102 is a recombinant AAVrh10 vector that expresses an anti-SOD1 artificial microRNA.
